Targeted screening for patients at highest genetic risk of prostate cancer increased clinical management, radical treatment

Offering targeted screening to participants in the 90th percentile of genetic risk as determined by a polygenic risk score resulted in finding prostate cancer warranting clinical management in 55.1% of patients and radical treatment in 21.4%, a U.K. study found.

Read the full article here

Related Articles

Spotlight on MASLD

Recent studies offered recommendations and evidence on screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis, as well as using medications to reduce the…